Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have earned an average rating of “Buy” from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $81.29.

A number of analysts recently commented on GPCR shares. JMP Securities reissued a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. William Blair assumed coverage on Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, Stifel Nicolaus assumed coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price on the stock.

Structure Therapeutics Trading Up 0.4 %

Shares of GPCR stock opened at $21.05 on Tuesday. Structure Therapeutics has a 12-month low of $19.39 and a 12-month high of $62.74. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -28.45 and a beta of -2.37. The stock has a 50 day simple moving average of $24.71 and a 200-day simple moving average of $31.63.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. On average, equities analysts forecast that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of Structure Therapeutics

Large investors have recently made changes to their positions in the stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Structure Therapeutics in the 4th quarter valued at about $3,091,000. GF Fund Management CO. LTD. acquired a new position in shares of Structure Therapeutics in the fourth quarter valued at approximately $34,000. Woodline Partners LP raised its position in shares of Structure Therapeutics by 0.7% in the fourth quarter. Woodline Partners LP now owns 333,901 shares of the company’s stock valued at $9,055,000 after buying an additional 2,328 shares during the last quarter. Vestal Point Capital LP lifted its stake in shares of Structure Therapeutics by 50.0% during the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after buying an additional 575,000 shares during the period. Finally, Twinbeech Capital LP boosted its position in Structure Therapeutics by 34.3% during the fourth quarter. Twinbeech Capital LP now owns 28,268 shares of the company’s stock worth $767,000 after acquiring an additional 7,220 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.